

European Healthcare Reforms: Any Relevance for the Rest of the World?

Reinhard Busse, Prof. Dr. med. MPH FFPH


Dept. Health Care Management, Technische Universität Berlin
(WHO Collaborating Centre for Health Systems Research and Management)

&

European Observatory on Health Systems and Policies





Third-party Payer







Population



Providers
























Development 3



~~Central~~ Regional governments


Questions arising:

- Funding from national or regional taxation?
- Benefit catalogue uniform?
- Supply density and quality regulated uniformly?
- Access to services across regional borders?

Population ~~Limited~~ Public providers
more choice







Main cost-sharing requirements since 2004

- **Pharmaceuticals:**
prescription drugs 10%, min. €5 (10 Sin\$), max. €10 (20 Sin\$) + amount above reference price, 0 if price max. 80% of reference price;
over-the-counter drugs normally 100%
- **Inpatient treatment:**
 €10 (20 Sin\$)/ day for max. 28 days/ year
- **Ambulatory medical and dental treatment:**
 €10 (20 Sin\$) per first visit in every quarter and for visits without referral


Fear “chronically ill don’t go to physicians“
was not true!

	Not chronically ill	Chronically ill
With visit 2003	69.4%	92.2%
2004	68.2%	93.6%
Number of visits 2003	2.51	6.09
2004	2.28	6.06

Grabka, Schreyögg, Busse 2006


Total expenditure of Statutory Health Insurance (GKV)

Source: Federal Statistical Office, Health Expenditure, Wiesbaden 2006




Expenditure of Statutory Health Insurance (GKV) in 2005 in %

(Source: Ministry of Health, <http://www.bmg.bund.de>, endgültige Rechnungsergebnisse der gesetzlichen Krankenversicherungen 2005)





Problem 2: Pharmaceutical expenditure



Spending caps: effective for cost-containment but politically unsustainable



Problem 3: Quality and cost-effectiveness

- Germany always knew that its health care system was expensive, but was sure it was worth it (“the best system“)
- Quality assurance was introduced early but concentrated on structure
- But increasing doubts since late 1990s: Health Technology Assessment introduced since 1997
- World Health Report 2000: Germany only # 25 in terms of performance (efficiency)
- International comparative studies demonstrate only average quality (especially low for chronically ill)










Disease Management Programmes (since 2002)

- **Compensate sickness funds for chronically ill better** (make them attractive) = reduce faulty incentives to attract young & healthy
- **Address quality problems** by guidelines/ pathways
- **Tackle trans-sectoral problems** by “integrated“ contracts
- = **introduce Disease Management Programs** meeting certain minimum criteria and compensate sickness funds for average expenditure of those enrolling (new RSC categories)

*double incentive for sickness funds:
potentially lower costs + extra compensation!*








Switzerland - the alternative? Premia in 2005 by canton (in CHF/ month)

Grafik 3e: Verteilung der kantonalen monatlichen Durchschnittsprämien für Erwachsene (26 Jahre und mehr) in Franken für 2005 (mit ordentlicher Franchise und Unfaldeckung)



Note:
1 CHF = 1.3 S\$

Or going Dutch? Pre- or post-2006 reform?

